ALLERGAN - Laserfiche WebLink

Home Browse Search

DocuSig�q Envelope ID: B15AAEBD-74AB-4EFF-B97F-0776E33BOD86 A-2023-060-05 EXHIBIT K Subdivision and Special District Settlement Participation Form Will your subdivision or special district be signing the settlement participation forms for the Allergan and Teva Settlements at this time? M Yes [ ] No Governmental Entity: Santa Ana city State: CA Authorized Signatory: Kristine Ridge, City Manager Address 1: 20 Civic Center Plaza Address 2: P.O. Box 1988 City, State, Zip: Santa Ana CA 92702 Phone: 714-647-5222 Email: kridge@santa-ana.org The governmental ;entity identified. above ("Governmental Entity") in order. to .obtain and, in consideration for thebenefitsprovided to the Governmental Entity pursuant to the Agreement dated November 22, 2022 ("Allergan Settlement."), and acting through the undersigned authorized official, hereby elects to participate in the Allergan Settlement, release all Released Claims against ,all Released:. Entities, and agrees as follows. 1. The Governmental Entity is aware of and has reviewed the Allergan, Settlement, understands that all terms in this Election and Release have the meanings defined therein, and agrees that by this Election, the Governmental Entity elects to participate in the Allergan Settlement: as provided therein. 2. Following the execution,ofthis Settlement Participation Form, the Governmental Entity shall: comply with Section lILB of the Allergan Settlement regarding Cessation of Litigation Activities. 3. The Governmental Entity shall, within fourteen (14) days of the Reference Date and prior to the filing of the Consent Judgment, file a request to dismiss with prejudice any Released Claims that it has filed. With respect to any Released Claims pending in In re National Prescription Opiate Litigation, NIDL No. 2804, the Governmental Entity authorizes the NIDL Plaintiffs' Executive Committee to execute and file on behalf of the Governmental Entity a Stipulation of Dismissal With Prejudice substantially in the form found at htti2s://nationalopioidsettlement.com 4. The Governmental Entity agrees to the terms of the Allergan Settlement pertaining to Subdivisions and Special Districts as defined therein. 5. By agreeing to the terms of the Allergan Settlement and becoming a Releasor, the Governmental Entity is entitled to the benefits provided therein, including, if applicable, monetary payments beginning after the Effective Date. 6. The Governmental Entity agrees to use any monies it receives through the Allergan Settlement solely for the purposes provided therein.